尿枸橼酸与早期多囊肾病的肾脏结局相关。
Urinary Citrate Is Associated with Kidney Outcomes in Early Polycystic Kidney Disease.
机构信息
Division of Nephrology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
出版信息
Kidney360. 2022 Oct 17;3(12):2110-2115. doi: 10.34067/KID.0004772022. eCollection 2022 Dec 29.
Abstract
Low urinary citrate and crystal deposition accelerated cystogenesis in an experimental model of polycystic kidney disease (PKD).Hypocitraturia, frequently observed in patients with autosomal dominant PKD (ADPKD) could contribute to disease progression.Present findings suggest lower urinary citrate in early PKD was associated with faster eGFR decline and worse kidney survival.
摘要
低尿枸橼酸和晶体沉积加速多囊肾病（PKD）实验模型中的囊泡形成。常观察到常染色体显性多囊肾病（ADPKD）患者的低枸橼酸尿症可能导致疾病进展。本研究结果表明，早期 PKD 患者的尿枸橼酸水平较低与 eGFR 下降更快和肾脏预后更差相关。
相似文献
1
Urinary Citrate Is Associated with Kidney Outcomes in Early Polycystic Kidney Disease.
Kidney360. 2022 Oct 17;3(12):2110-2115. doi: 10.34067/KID.0004772022. eCollection 2022 Dec 29.
2
Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease.
Int Urol Nephrol. 2022 Apr;54(4):873-881. doi: 10.1007/s11255-021-02953-0. Epub 2021 Jul 19.
3
Hypocitraturia is present when renal function is impaired in diverse nephropathies and is not related with serum bicarbonate levels.
Int Urol Nephrol. 2022 Jun;54(6):1261-1269. doi: 10.1007/s11255-021-02992-7. Epub 2021 Sep 21.
4
Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.
J Clin Invest. 2019 Jul 30;129(10):4506-4522. doi: 10.1172/JCI128503.
5
Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Am J Nephrol. 2019;50(5):375-385. doi: 10.1159/000502999. Epub 2019 Oct 10.
6
Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study.
Clin Exp Nephrol. 2023 Nov;27(11):912-918. doi: 10.1007/s10157-023-02378-2. Epub 2023 Jul 26.
7
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.
8
Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Clin Exp Nephrol. 2021 Sep;25(9):970-980. doi: 10.1007/s10157-021-02068-x. Epub 2021 Apr 29.
9
KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
Am J Nephrol. 2020;51(6):473-479. doi: 10.1159/000508051. Epub 2020 Jun 15.
10
Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
J Med Econ. 2015 Apr;18(4):303-11. doi: 10.3111/13696998.2014.985381. Epub 2015 Jan 20.
引用本文的文献
1
A Urine pH-Ammonium Acid/Base Score and CKD Progression.
J Am Soc Nephrol. 2024 Nov 1;35(11):1533-1545. doi: 10.1681/ASN.0000000000000447. Epub 2024 Jul 17.
2
Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression.
Nutrients. 2024 Sep 27;16(19):3281. doi: 10.3390/nu16193281.
3
The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development.
BMC Med. 2023 Dec 18;21(1):504. doi: 10.1186/s12916-023-03227-5.
4
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease.
Am J Physiol Renal Physiol. 2024 Mar 1;326(3):F352-F368. doi: 10.1152/ajprenal.00205.2023. Epub 2023 Dec 14.
5
Kidney phosphate wasting predicts poor outcome in polycystic kidney disease.
Nephrol Dial Transplant. 2024 Jun 28;39(7):1105-1114. doi: 10.1093/ndt/gfad247.
6
Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial.
Cell Rep Med. 2023 Nov 21;4(11):101283. doi: 10.1016/j.xcrm.2023.101283. Epub 2023 Nov 7.
本文引用的文献
1
Total Kidney Volume Measurements in ADPKD by 3D and Ellipsoid Ultrasound in Comparison with Magnetic Resonance Imaging.
Clin J Am Soc Nephrol. 2022 Jun;17(6):827-834. doi: 10.2215/CJN.14931121. Epub 2022 Apr 5.
2
Hypocitraturia is present when renal function is impaired in diverse nephropathies and is not related with serum bicarbonate levels.
Int Urol Nephrol. 2022 Jun;54(6):1261-1269. doi: 10.1007/s11255-021-02992-7. Epub 2021 Sep 21.
3
Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease.
Int Urol Nephrol. 2022 Apr;54(4):873-881. doi: 10.1007/s11255-021-02953-0. Epub 2021 Jul 19.
4
Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant. 2021 Dec 2;36(12):2248-2255. doi: 10.1093/ndt/gfaa283.
5
Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease.
Kidney Int. 2021 Jan;99(1):208-217. doi: 10.1016/j.kint.2020.07.006. Epub 2020 Jul 25.
6
Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.
J Clin Invest. 2019 Jul 30;129(10):4506-4522. doi: 10.1172/JCI128503.
7
Metabolic abnormalities in autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant. 2015 Feb;30(2):197-203. doi: 10.1093/ndt/gfu044. Epub 2014 Mar 2.
8
Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.
Nat Med. 2013 Apr;19(4):488-93. doi: 10.1038/nm.3092. Epub 2013 Mar 24.
9
Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.
Clin J Am Soc Nephrol. 2009 Apr;4(4):838-44. doi: 10.2215/CJN.03100608. Epub 2009 Apr 1.
10
Unified criteria for ultrasonographic diagnosis of ADPKD.
J Am Soc Nephrol. 2009 Jan;20(1):205-12. doi: 10.1681/ASN.2008050507. Epub 2008 Oct 22.
Zotero 插件